Tivic Health Systems Inc., a diversified immunotherapeutics company, will participate in the Emerging Growth virtual conference on September 25, 2025. CEO Jennifer Ernst will present the company's strategic transformation into the biopharmaceutical sector, focusing on their lead commercial opportunity, Entolimod, for treating Acute Radiation Syndrome and their licensed indication for Neutropenia.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tivic Health Systems Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250922947023) on September 22, 2025, and is solely responsible for the information contained therein.
Comments